Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2

Matthew D. Resch(TechnoVax (United States)), Jose M. Galarza(TechnoVax (United States))
Vaccines
November 24, 2022
Cited by 10


Related Papers